|
nasopharyngeal carcinoma |
30 |
|
tumor microenvironment |
16 |
|
whole-exome sequencing |
16 |
|
prognostic marker |
15 |
|
metastasis |
14 |
|
cancer susceptibility genes |
13 |
|
early-age onset |
13 |
|
epstein-barr virus |
13 |
|
mst1r |
13 |
|
apobec-mediated signature |
12 |
|
nasopharyngeal carcinoma (npc) |
12 |
|
nf-κb signaling |
12 |
|
somatic mutation landscape |
12 |
|
esophageal squamous cell carcinoma (escc) |
11 |
|
nidogen-2 (nid2) |
11 |
|
npc |
11 |
|
promoter hypermethylation |
11 |
|
signal transduction |
11 |
|
dna methylation |
10 |
|
ebv |
10 |
|
liquid biopsy |
10 |
|
tissue microarray |
10 |
|
tumor suppressor |
10 |
|
chromatin accessibility |
9 |
|
chromosome 6p |
9 |
|
host-virus interaction |
9 |
|
illumina humanmethylation450 |
9 |
|
leucocyte telomere length |
9 |
|
methylome |
9 |
|
npc risk |
9 |
|
survival |
9 |
|
telomere biology |
9 |
|
whole-genome bisulfite sequencing |
9 |
|
circulating neoplastic cell |
8 |
|
circulating tumor cells |
8 |
|
circulating tumor dna |
8 |
|
medical sciences |
8 |
|
oncology |
8 |
|
blm |
7 |
|
ccdc170 |
7 |
|
cell-free dna |
7 |
|
ctc enumeration |
7 |
|
dna dsb repair |
7 |
|
esophageal squamous cell carcinoma |
7 |
|
familial npc |
7 |
|
genetic susceptibility |
7 |
|
longitudinal real-time monitoring |
7 |
|
nhej |
7 |
|
non-invasive biomarker |
7 |
|
nucleosome organization |
7 |
|
oesophageal squamous cell carcinoma |
7 |
|
pathway associations |
7 |
|
tert |
7 |
|
whole‐exome sequencing |
7 |
|
znf750 mutation |
7 |
|
autoimmune disease |
6 |
|
biomarker |
6 |
|
biomarkers |
6 |
|
cancer immunosuppression |
6 |
|
cell signaling |
6 |
|
covid-19 |
6 |
|
dna damage repair pathway |
6 |
|
double-negative b cells |
6 |
|
early diagnosis |
6 |
|
enzyme-linked immunosorbent assay |
6 |
|
epstein−barr virus |
6 |
|
extracellular matrix protein |
6 |
|
histone bivalent switch |
6 |
|
human leukocyte antigen |
6 |
|
inflammation |
6 |
|
mlh1 |
6 |
|
ms‐hrm |
6 |
|
nidogen-2 |
6 |
|
npc genetics |
6 |
|
serum biomarker |
6 |
|
cisplatin |
5 |
|
cytotoxicity |
5 |
|
enox2 |
5 |
|
epstein–barr virus infection |
5 |
|
esophageal cancer |
5 |
|
idronoxil |
5 |
|
immune regulation |
5 |
|
invadopodia |
5 |
|
invasion |
5 |
|
latent membrane protein 1 |
5 |
|
live-cell imaging |
5 |
|
memory t-cells |
5 |
|
nasophanrygeal carcinoma |
5 |
|
precision medicine |
5 |
|
protein translation |
5 |
|
single-cell sequencing |
5 |
|
tumor microenvionment |
5 |
|
tumor-associated macrophage |
5 |
|
apoptosis |
4 |
|
breast cancer |
4 |
|
ct dna |
4 |
|
diagnosis |
4 |
|
differentially expressed in squamous cell carcinoma 1 |
4 |
|
ebv bart mirnas |
4 |
|
ebv serology |
4 |
|
genomic instability |
4 |
|
histone modification |
4 |
|
innate immune response |
4 |
|
methylation |
4 |
|
ngs analysis |
4 |
|
plasma ebv dna |
4 |
|
polq |
4 |
|
telomere length |
4 |
|
transmembrane serine protease |
4 |
|
anti-cancer therapy |
3 |
|
asian continental ancestry group - genetics |
3 |
|
cancer metastasis |
3 |
|
cancer prognosis |
3 |
|
cell signaling pathways |
3 |
|
crispr/cas9 screening |
3 |
|
cylindromatosis lysine 63 deubiquitinase (cyld) |
3 |
|
deep learning |
3 |
|
dna repair gene |
3 |
|
epigenetics |
3 |
|
epstein–barr virus |
3 |
|
genetic predisposition |
3 |
|
genetic predisposition to disease |
3 |
|
genome-wide association study |
3 |
|
germline polymorphisms |
3 |
|
gwas |
3 |
|
hla |
3 |
|
low-dose volume |
3 |
|
lymphopenia |
3 |
|
natural killer cells |
3 |
|
nf-kb |
3 |
|
noncoding rna |
3 |
|
pancreatic neoplasms - genetics |
3 |
|
polymorphism, single nucleotide |
3 |
|
protein interactome |
3 |
|
radiotherapy (rt) |
3 |
|
rpa1 |
3 |
|
telomere |
3 |
|
tumor immune microenvironment |
3 |
|
whole-exome sequencing (wes) |
3 |
|
cancer vaccine |
2 |
|
cellular therapy |
2 |
|
exosomes |
2 |
|
extracellular vesicles |
2 |
|
immune checkpoint inhibitors |
2 |
|
tumour microenvironment |
2 |
|
ascites |
1 |
|
breast cancer campaign tissue bank |
1 |
|
breast epithelial cells |
1 |
|
breast milk |
1 |
|
cell survival |
1 |
|
cluster analysis |
1 |
|
cohort analysis |
1 |
|
cpg islands |
1 |
|
cystadenocarcinoma, serous - drug therapy - genetics - mortality - pathology |
1 |
|
ovarian neoplasms - drug therapy - genetics - metabolism - mortality - pathology |
1 |
|
promoter regions, genetic |
1 |
